Research, Select, & Monitor Saturday, May 30, 2020 5:32:53 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
ImmunoGen, Inc.$4.68($.12)(2.50%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  ImmunoGen, Inc. vs Drug Manufacturers/Other

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $82.3 Mil $85,825.5 Mil
  Market Cap: $781.3 Mil $360,459.6 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
  Historic Revenue: 53.9% 209.0%
  Estimated Revenue: (24.4%) (1.5%)
  Historic Earnings: N/A (11.7%)
  Estimated Earnings: N/A 151.3%
  Stock Price (1 Year): 148.9% 38.9%
  Cash per Share: (33.1%) (2.7%)
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: N/A 24.0
  Price-to-Sales: 9.0 N/A
  Price-to-Book: (9.2) 4.9
  Dividend Yield: N/A N/A
  Market Cap: $781.3 Mil $15,019.1 Mil
  Net Margin: (102.9%) (1,002.4%)
  Gross Margin: 100.0% 84.4%
  Return on Equity: N/A (.3)
  Return on Assets: (.4) (.2)
  Balance Sheet
  Current Ratio: 2.7 9.6
  Quick Ratio: 2.7 9.4
  Cash Ratio: 2.3 8.1
  Debt-to-Equity: N/A 2.0
  Interest Coverage: .3 1.2
  Relative-Strength Index: 56.1 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $65.94 $155,344.2 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $287.96 $75,881.8 Mil
  UBS AG  (UBS) $10.70 $39,662.4 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $119.90 $26,689.7 Mil
  BioMarin Pharmaceutical, Inc.  (BMRN) $106.55 $19,942.2 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.